Several studies using 177Lu-LNC1004 (Fu et al., 2023), 177Lu-DOTAGA.(SA.FAPi)2 (Ballal et al., 2021b), and 177Lu-DOTAGA.FAPi dimers (Ballal et al., 2025) to treat patients with iodine-refractory thyroid cancer have shown partial remissions, pain relief and reduced thyroglobulin (Tg) levels in these patients. The gene discussed is TG; the disease is thyroid cancer.